Prevalence and Predictors of Distress in Posttreatment Adult Leukemia and Lymphoma Survivors

Jones, Whitney C.; Parry, Carla; Devine, Sharon; Main, Deborah S.; Okuyama, Sonia; Tran, Zung Vu

doi:10.1080/07347332.2014.992085

Cited by 20 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six of the studies were from the USA (Cella & Tross, ; Jones, Parry, Devine, Main, & Okuyama, ; Jones, Parry, Devine, Main, Okuyama, et al., ; Parry, Morningstar, Kendall, & Coleman, ; Smith, Crespi, Petersen, Zimmerman, & Ganz, , Smith, Zimmerman, Williams, & Zebrack, ), and one was from the UK (Pettengell et al., ). All studies reported data from a sample with a similar mean age (ranging between 50.3 and 62.7), except Cella and Tross () whose participants had a considerably younger mean age of 31.1 years.…”

Section: Methodsmentioning

confidence: 99%

“…The studies included samples of participants who had been diagnosed with various types of leukaemia and/or lymphoma. Three studies included leukaemia and lymphoma patients (Jones, Parry, Devine, Main, & Okuyama, ; Jones, Parry, Devine, Main, Okuyama, et al., ; Parry et al., ), two Non‐Hodgkin's lymphoma (NHL), one Hodgkin's disease (HD) and one follicular lymphoma (a type of NHL). All studies were published between 2008 and 2015 except the Cella and Tross () study which is considerably older being published in 1986.…”

Section: Methodsmentioning

confidence: 99%

“…However, all the quantitative studies used instruments that measure some form of distress, and the two qualitative studies included questions that explored distress in some manner. Quantitative studies measured psychological adjustment (Cella & Tross, ), cancer‐specific distress (Jones, Parry, Devine, Main, Okuyama, et al., ), depression and anxiety (Pettengell et al., ), post‐traumatic stress disorder (Smith et al., ), mental health, emotional wellbeing (Smith et al., , ). The two qualitative studies looked at how lifespan stage shapes the nature of distress (Jones, Parry, Devine, Main, & Okuyama, ) and survivor perspectives on care delivery and supportive care needs at the end of treatment.…”

Section: Methodsmentioning

confidence: 99%

“…However, as such different methods, measures and samples were used, it was hard to compare the results. Four publications report clear indicators of distress in their studies (Jones, Parry, Devine, Main, & Okuyama, ; Jones, Parry, Devine, Main, Okuyama, et al., ; Parry et al., , Smith et al., ).…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Psychosocial distress in haematological cancer survivors: An integrative review

2017

View full text Add to dashboard Cite

Haematological cancers are becoming more prevalent, however, survival is also increasing. Many survivors are faced with psychosocial issues after treatment ends, and they may not receive the support they need. This review aims to examine peer reviewed literature reporting psychosocial distress faced by haematological cancer survivors in the early post-treatment period. Database and hand searches were conducted between August and September 2015, with no year restriction. Eligible studies were those reporting on psychosocial sequelae in haematological cancer survivors up to 5 years post-treatment. The search yielded 512 studies, of these only seven (five quantitative and two qualitative) included data that addressed psychosocial distress in early post-treatment haematological cancer survivors. Data were thematically analysed to explore the presence and nature of distress. Most studies reported mild to moderate distress for survivors, with some evidence that younger age was an indicator of increased distress. However, predominately this review identified a gap in current literature regarding distress among this group of survivors. More research is needed to address the psychosocial issues facing this growing survivor group, to enable them to receive the support required to maintain good physical and psychological health in this period of the cancer trajectory and into the future.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Psychosocial distress in haematological cancer survivors: An integrative review

2017

View full text Add to dashboard Cite

show abstract

“…Gerade für jüngere Patienten wurde in der jüngsten Zeit in 2 weiteren aktuellen Studien gezeigt, dass auch nach dem Überleben anderer bösartiger Erkrankungen, wie z. B. von akuten Leukämien oder Lymphomen, höhere psychosoziale Belastungen vorliegen als bei älte-ren Patienten [27] und diese Belastungen auch noch Jahre nach einer erfolgreichen Behandlung nachweisbar sind [28].…”

Section: Chronisch Myeloische Leukämieunclassified

Psychosoziale Aspekte bei seltenen onkologischen Erkrankungen

Panse

2015

Onkologe

View full text Add to dashboard Cite

Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia

et al. 2021

View full text Add to dashboard Cite

IMPORTANCEPatients with acute myeloid leukemia (AML) receiving intensive chemotherapy experience substantial decline in their quality of life (QOL) and mood during their hospitalization for induction chemotherapy and often receive aggressive care at the end of life (EOL). However, the role of specialty palliative care for improving the QOL and care for this population is currently unknown.OBJECTIVE To assess the effect of integrated palliative and oncology care (IPC) on patient-reported and EOL outcomes in patients with AML. DESIGN, SETTING, AND PARTICIPANTSWe conducted a multisite randomized clinical trial of IPC (n = 86) vs usual care (UC) (n = 74) for patients with AML undergoing intensive chemotherapy. Data were collected from January 2017 through July 2019 at 4 tertiary care academic hospitals in the United States.INTERVENTIONS Patients assigned to IPC were seen by palliative care clinicians at least twice per week during their initial and subsequent hospitalizations. MAIN OUTCOMES AND MEASURESPatients completed the 44-item Functional Assessment of Cancer Therapy-Leukemia scale (score range, 0-176) to assess QOL; the 14-item Hospital Anxiety and Depression Scale (HADS), with subscales assessing symptoms of anxiety and depression (score range, 0-21); and the PTSD Checklist-Civilian version to assess posttraumatic stress disorder (PTSD) symptoms (score range, 17-85) at baseline and weeks 2, 4, 12, and 24. The primary end point was QOL at week 2. We used analysis of covariance adjusting and mixed linear effect models to evaluate patient-reported outcomes. We used Fisher exact test to compare patient-reported discussion of EOL care preferences and receipt of chemotherapy in the last 30 days of life. RESULTSOf 235 eligible patients, 160 (68.1%) were enrolled; of the 160 participants, the median (range) age was 64.4 (19.7-80.1) years, and 64 (40.0%) were women. Compared with those receiving UC, IPC participants reported better QOL (adjusted mean score, 107.59 vs 116.45; P = .04), and lower depression (adjusted mean score, 7.20 vs 5.68; P = .02), anxiety (adjusted mean score, 5.94 vs 4.53; P = .02), and PTSD symptoms (adjusted mean score, 31.69 vs 27.79; P = .01) at week 2. Intervention effects were sustained to week 24 for QOL (β, 2.35; 95% CI, 0.02-4.68; P = .048), depression (β, −0.42; 95% CI, −0.82 to −0.02; P = .04), anxiety (β, −0.38; 95% CI, −0.75 to −0.01; P = .04), and PTSD symptoms (β, −1.43; 95% CI, −2.34 to −0.54; P = .002). Among patients who died, those receiving IPC were more likely than those receiving UC to report discussing EOL care preferences (21 of 28 [75.0%] vs 12 of 30 [40.0%]; P = .01) and less likely to receive chemotherapy near EOL (15 of 43 [34.9%] vs 27 of 41 [65.9%]; P = .01). CONCLUSIONS AND RELEVANCEIn this randomized clinical trial of patients with AML, IPC led to substantial improvements in QOL, psychological distress, and EOL care. Palliative care should be considered a new standard of care for patients with AML.

show abstract

Prevalence and Predictors of Distress in Posttreatment Adult Leukemia and Lymphoma Survivors

Cited by 20 publications

References 43 publications

Psychosocial distress in haematological cancer survivors: An integrative review

Psychosocial distress in haematological cancer survivors: An integrative review

Psychosoziale Aspekte bei seltenen onkologischen Erkrankungen

Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia

Contact Info

Product

Resources

About